Literature DB >> 20644120

How I treat elderly patients with myeloma.

Jayesh Mehta1, Michele Cavo, Seema Singhal.   

Abstract

The clinical approach to older patients with myeloma has to be modified to take into account comorbidities and the likelihood of higher treatment-related toxicity. Individualization of management and adequate supportive therapy are important to obtain the best response while minimizing adverse effects. Corticosteroids, novel agents, conventional cytotoxic agents, and high-dose chemotherapy with autotransplantation (modalities used in younger patients) are also used in older patients, although the elderly undergo transplantation less frequently. The sequential use of active agents singly and in different combinations has improved response rates and survival of all patients with myeloma, including the elderly.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20644120     DOI: 10.1182/blood-2009-10-163329

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  15 in total

1.  Undertreatment of Older Patients With Newly Diagnosed Multiple Myeloma in the Era of Novel Therapies.

Authors:  Bita Fakhri; Mark A Fiala; Sascha A Tuchman; Tanya M Wildes
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2018-01-31

Review 2.  Management of Newly Diagnosed Elderly Multiple Myeloma Patients.

Authors:  Crystal Antoine-Pepeljugoski; Marc Justin Braunstein
Journal:  Curr Oncol Rep       Date:  2019-05-24       Impact factor: 5.075

3.  The Singapore Myeloma Study Group Consensus Guidelines for the management of patients with multiple myeloma.

Authors:  Sanjay de Mel; Yunxin Chen; Sathish Kumar Gopalakrishnan; Melissa Ooi; Constance Teo; Daryl Tan; Min Li Claire Teo; Allison Cy Tso; Lian King Lee; Chandramouli Nagarajan; Yeow Tee Goh; Wee Joo Chng
Journal:  Singapore Med J       Date:  2016-09-09       Impact factor: 1.858

4.  European Myeloma Network guidelines for the management of multiple myeloma-related complications.

Authors:  Evangelos Terpos; Martina Kleber; Monika Engelhardt; Sonja Zweegman; Francesca Gay; Efstathios Kastritis; Niels W C J van de Donk; Benedetto Bruno; Orhan Sezer; Annemiek Broijl; Sara Bringhen; Meral Beksac; Alessandra Larocca; Roman Hajek; Pellegrino Musto; Hans Erik Johnsen; Fortunato Morabito; Heinz Ludwig; Michele Cavo; Hermann Einsele; Pieter Sonneveld; Meletios A Dimopoulos; Antonio Palumbo
Journal:  Haematologica       Date:  2015-10       Impact factor: 9.941

5.  New Treatment Approaches for Older Adults with Multiple Myeloma.

Authors:  Tanya M Wildes; Ravi Vij; Stephen H Petersdorf; Bruno C Medeiros; Arti Hurria
Journal:  J Geriatr Oncol       Date:  2012-02-28       Impact factor: 3.599

6.  Patient, Physician and Contextual Factors Are Influential in the Treatment Decision Making of Older Adults Newly Diagnosed with Symptomatic Myeloma.

Authors:  Joseph D Tariman; Ardith Doorenbos; Karen G Schepp; Pamela S Becker; Donna L Berry
Journal:  Cancer Treat Commun       Date:  2014

Review 7.  Challenges and Strategies in the Management of Multiple Myeloma in the Elderly Population.

Authors:  Saurabh Zanwar; Jithma Prasad Abeykoon; Prashant Kapoor
Journal:  Curr Hematol Malig Rep       Date:  2019-04       Impact factor: 3.952

8.  Maytansinoid immunoconjugate IMGN901 is cytotoxic in a three-dimensional culture model of multiple myeloma.

Authors:  Brittany A Nierste; Ellen J Gunn; Kathleen R Whiteman; Robert J Lutz; Julia Kirshner
Journal:  Am J Blood Res       Date:  2016-05-18

9.  European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma.

Authors:  Monika Engelhardt; Evangelos Terpos; Martina Kleber; Francesca Gay; Ralph Wäsch; Gareth Morgan; Michele Cavo; Niels van de Donk; Andreas Beilhack; Benedetto Bruno; Hans Erik Johnsen; Roman Hajek; Christoph Driessen; Heinz Ludwig; Meral Beksac; Mario Boccadoro; Christian Straka; Sara Brighen; Martin Gramatzki; Alessandra Larocca; Henk Lokhorst; Valeria Magarotto; Fortunato Morabito; Meletios A Dimopoulos; Hermann Einsele; Pieter Sonneveld; Antonio Palumbo
Journal:  Haematologica       Date:  2014-02       Impact factor: 9.941

10.  Design and rationale of FOCUS (PX-171-011): a randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM).

Authors:  Roman Hájek; Richard Bryce; Sunhee Ro; Barbara Klencke; Heinz Ludwig
Journal:  BMC Cancer       Date:  2012-09-19       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.